Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature

Background: The introduction of checkpoint inhibitors is a long-awaited new option for a urothelial cancer with a poor prognosis. Apart from clinical studies, the data on real world experience is scarce. Methods: Patients for monotherapy with either Atezolizumab, Nivolumab or Pembrolizumab after che...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuhrmann, Christian, Struck, Julian P., Ivanyi, Philipp, Kramer, Mario W., Hupe, Marie C., Hensen, Bennet, Fürschke, Alexander, Peters, Inga, Merseburger, Axel S., Kuczyk, Markus A., von Klot, Christoph-A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253725/
https://www.ncbi.nlm.nih.gov/pubmed/32528889
http://dx.doi.org/10.3389/fonc.2020.00808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253725/
https://www.ncbi.nlm.nih.gov/pubmed/32528889
http://dx.doi.org/10.3389/fonc.2020.00808

Ejemplares similares